STML

Stemline Therapeutics Inc

Healthcare


Presented:03/06/2019
Price:$11.02
Cap:$0.45B
Current Price:$11.83
Cap:$0.62B

Presented

Date03/06/2019
Price$11.02
Market Cap$0.45B
Ent Value$0.40B
P/E RatioN/A
Book Value$2.01
Div Yield0%
Shares O/S40.56M
Ave Daily Vol688,241
Short Int10.81%

Current

Price$11.83
Market Cap$0.62B
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Publicly traded companies mentioned herein: Stemline Therapeutics Inc (STML)

Highlights

The presenter is long Stemline Therapeutics (STML) and believes the Street is underestimating the launch curve for Elzonris (tagraxofusp, SL-401), which was approved on Dec 21, 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). He expects STML to beat Street estimates in Q1’19 (est 3/25, 8am/BMO), and when it becomes clearer to analysts and investors how much Elzonris is needed to treat BPDCN (i.e., how many cycles patients may receive), revenue estimates should need to be revised higher (closer to $60MM for the year, versus $35MM). With the stock trading in the $11 - $12 range and optionality around European approval and expansion of [Elzonris’] use to include CMML and MF, the risk/reward favors bulls. If all goes well for STML, the fair value estimate for the stock is ~$37.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.